Prothena Corporation (PRTA) saw its loss widen to $43.24 million, or $1.26 a share for the quarter ended Sep. 30, 2016. In the previous year period, the company reported a loss of $22.98 million, or $0.73 a share.     

Revenue during the quarter plunged 33.33 percent to $0.29 million from $0.43 million in the previous year period.    

Operating loss for the quarter was $42.69 million, compared with an operating loss of $22.66 million in the previous year period.

"With the continued expansion of our team and capabilities, we are advancing our vision of establishing a fully-integrated biotechnology company that can take a potential new therapy from discovery to patients," stated Gene Kinney, PhD, president and chief executive officer of Prothena. "During the next 18 months, we expect to achieve significant milestones for each of our clinical programs. Later this month, we plan to report topline data from the Phase 1b multiple ascending dose study for PRX002 in patients with Parkinson’s disease, and in 2017 we expect both interim and full results from the Phase 1b proof-of-biology study of PRX003 in patients with psoriasis. For our lead program NEOD001, the VITAL study is on track to be fully enrolled by the second quarter of 2017 and based on the current status of the PRONTO study enrollment, we expect topline results from this study in early 2018.

Days sales outstanding went down to 155 days for the quarter compared with 190 days for the same period last year.